PNTG

Wells Fargo Upgrade: On November 18, 2025, Wells Fargo upgraded Pennant Group's outlook from Equal-Weight to Overweight, with an average one-year price target of $34.00/share, indicating a potential upside of 33.86% from its closing price of $25.40/share.

Institutional Ownership Trends: There are 401 funds reporting positions in Pennant Group, reflecting a 7.22% increase in ownership over the last quarter, with total shares owned by institutions rising by 2.79% to 35,470K shares.

Fund Sentiment: The put/call ratio for Pennant Group is 0.92, suggesting a bullish sentiment among investors, while several firms have adjusted their portfolio allocations, with some increasing and others decreasing their holdings.

Projected Financials: The projected annual revenue for Pennant Group is estimated at $550 million, representing a decrease of 35.06%, with a projected non-GAAP EPS of 0.98.

Earnings Performance: The Pennant Group, Inc. reported quarterly earnings of $0.30 per share, exceeding the Zacks Consensus Estimate of $0.29, and showing an increase from $0.26 per share a year ago. The company has surpassed consensus EPS estimates three out of the last four quarters.

Revenue Growth: The company generated revenues of $229.04 million for the quarter, surpassing the Zacks Consensus Estimate by 2.71% and up from $180.69 million year-over-year. It has also topped revenue estimates in all four of the last quarters.

Stock Outlook: Despite the positive earnings report, The Pennant Group's shares have declined by 4.7% since the start of the year, underperforming the S&P 500's 15.1% gain. The stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.

Industry Context: The Medical - Outpatient and Home Healthcare industry, to which The Pennant Group belongs, is currently ranked in the top 18% of Zacks industries, suggesting a favorable outlook. Investors are advised to monitor earnings estimate revisions for future performance insights.